← Back to Search

Procedure

Ablation for Liver Cancer

Q: Are researchers still enrolling participants for this experiment?

<p>This clinical trial remains open to participants, as evidenced by its listing on clinicaltrials.gov. This research was first made available back in October 2009 and has been updated more recently this April.</p>

Q: What is the cap on enrollment for this research initiative?

<p>Affirmative. Clinicaltrials.gov records indicate that this medical trial, originally uploaded on October 27th 2009, is currently in recruitment mode and seeking 160 subjects at 1 different centre.</p>

N/A

Recruiting

Led By Constantinos Sofocleous, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients diagnosed with secondary hepatic malignancy

Patients with confined liver disease or stable limited extrahepatic disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is to study whether a particular test can show if the ablation worked in treating the tumor.

Who is the study for?

This trial is for adults with liver tumors no larger than 5cm, who aren't surgical candidates or prefer not to have surgery. They should have a stable blood clotting measure (INR<1.5), enough platelets, and either confined liver disease or limited stable disease outside the liver.Check my eligibility

What is being tested?

The study tests if analyzing tissue from ablated malignant liver metastases can predict treatment success. It involves CT-guided percutaneous ablation—a minimally invasive procedure—and examines whether new growths are cancerous post-treatment.See study design

What are the potential side effects?

While specific side effects are not listed here, percutaneous ablation procedures may include risks such as pain at the site of treatment, bleeding, infection, and damage to nearby organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with cancer that has spread to my liver.

Select...

My cancer is mainly in my liver or is stable and not widely spread.

Select...

My cancer lesion is 5cm or smaller.

Select...

I am choosing a non-surgical treatment option instead of surgery.

Select...

My blood clotting time is within a safe range for a procedure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Tumor response

Secondary outcome measures

Duration of treatment response

Trial Design

1Treatment groups

Experimental Treatment

Group I: CT guided percutaneous ablationExperimental Treatment1 Intervention

The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Rockefeller UniversityOTHER

158 Previous Clinical Trials

16,197 Total Patients Enrolled

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,935 Previous Clinical Trials

588,695 Total Patients Enrolled

20 Trials studying Liver Cancer

7,686 Patients Enrolled for Liver Cancer

Constantinos Sofocleous, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

Liver Cancer Research Study Groups: CT guided percutaneous ablation

Liver Cancer Clinical Trial 2023: CT guided percutaneous ablation Highlights & Side Effects. Trial Name: NCT01494324 — N/A

CT guided percutaneous ablation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01494324 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers still enrolling participants for this experiment?

"This clinical trial remains open to participants, as evidenced by its listing on clinicaltrials.gov. This research was first made available back in October 2009 and has been updated more recently this April."

Answered by AI

What is the cap on enrollment for this research initiative?

"Affirmative. Clinicaltrials.gov records indicate that this medical trial, originally uploaded on October 27th 2009, is currently in recruitment mode and seeking 160 subjects at 1 different centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

2009. "Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01494324.

All > Liver Fibrosis > Liver Cancer